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precursor protein cleaving enzyme-1 (BACE1) levels and proteolytic products of amyloid precursor protein
and neuregulin-1 point toward a possible association of altered BACE1 activity in association with altered
apoD levels. In conclusion, the current studies provide clear evidence that apoD regulates amyloid plaque
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ABSTRACT

Apolipoprotein-D (apoD) is expressed in the brain and levels are increased in affected brain
regions in Alzheimer’s disease (AD). The role that apoD may play in regulating AD
pathology has not been addressed. Here we crossed both apoD null mice and Thy-1 human
apoD transgenic mice with APP-PS1 amyloidogenic AD mice. Loss of apoD resulted in an ~
2-fold increase in hippocampal amyloid plaque load assessed by immunohistochemical
staining. Conversely, transgenic expression of neuronal apoD reduced hippocampal plaque
load by ~ 35%. This latter finding was associated with a 60% decrease in amyloid-beta 1-40
peptide levels, and a 34% decrease in insoluble amyloid-beta 1-42 peptide. Assessment of
beta-site amyloid precursor protein cleaving enzyme-1 (BACE1) levels and proteolytic
products of amyloid precursor protein and neuregulin-1 point towards a possible association
of altered BACE1 activity in association with altered apoD levels. In conclusion, the current
studies provide clear evidence that apoD regulates amyloid plaque pathology in a mouse
model of AD.
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Abbreviations: A, amyloid-beta peptide; AD, Alzheimer’s disease; apoD, apolipoproteinD; BACE1, beta-site amyloid precursor protein cleaving enzyme-1; BCA, bicinchoninic acid;
BHT, butylated hydroxytoluene; CTFs, C-terminal fragments; DKO, apoD gene knockout
mice; DTG, human apoD transgenic mice; L-OOH, lipid hydroperoxide; MTBE, Methyl-tertbutyl ether; ThS, thioflavine S
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1. Introduction

ApoD is expressed in the brain and levels are increased during brain development and aging
(Kim et al., 2009). It is also established that apoD levels are increased in affected brain
regions in Alzheimer’s disease (AD) and in AD mouse models (Bhatia et al., 2013; Terrisse
et al., 1998; Thomas et al., 2003; Thomas et al., 2001). Additional studies show that brain
lipid peroxidation is increased during aging (Cristiano et al., 1995; Droge and Schipper,
2007), as well as in AD and AD mouse models (Abdul et al., 2008; Markesbery and Carney,
1999; Montine et al., 2007; Sayre et al., 1997; Schuessel et al., 2005). Furthermore, recent
studies show that the increase in apoD associated with aging and AD in human brain tissues
is correlated with markers of lipid oxidative stress (Bhatia et al., 2013; Kim et al., 2009).
These findings are particularly pertinent as a novel role for apoD in the control of brain lipid
peroxidation has been reported (Bajo-Graneras et al., 2011; Bajo-Graneras et al., 2011;
Ganfornina et al., 2008). Studies in mice revealed that brain apoD is induced in response to
oxidative stress, that lipid peroxidation is increased in the brains of apoD null mice, and that
neuronal expression of human apoD prevents brain lipid peroxidation in response to
paraquat-induced oxidative stress (Ganfornina et al., 2008).

One mechanism by which apoD acts as a lipid antioxidant involves the interaction of a single
conserved Met residue located within the hydrophobic patch at the entrance of the apoD
ligand binding pocket (Bhatia et al., 2012; Oakley et al., 2012). The apoD Met93 residue
interacts directly with potentially reactive radical-generating lipid hydroperoxide (L-OOH)
species, converting them to non-reactive lipid hydroxides, an antioxidant activity that is lost
when Met93 is replaced with Ala (Bhatia et al., 2012). One consequence of this reaction is the
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formation of a Met-sulfoxide residue that destabilizes the protein and promotes its noncovalent dimerization (Bhatia et al., 2012). Interestingly, apoD dimers have been identified in
the hippocampus, but not in the pathologically spared cerebellum, of human AD subjects
(Bhatia et al., 2013). There is now a growing consensus that apoD may play a protective role
in AD, and other neurological diseases (Bhatia et al., 2013; Dassati et al., 2014).

One important question that remains unanswered centres on the postulated protective
function of apoD in AD and whether it could modulate pathological processes (including
those associated with amyloid plaque pathology and lipid peroxidation) or simply represent a
marker of disease progression. Based on the studies cited above, we hypothesized that apoD
gene deletion may exacerbate the AD phenotype in amyloidogenic AD mice whereas early
over-expression of apoD in neurons would have the opposite effect, and reduce the AD
amyloidogenic phenotype. In the current study we have addressed this hypothesis by crossing
apoD null mice, as well as transgenic mice expressing human apoD in neurons, with
APP/PS1 amyloidogenic mice and assessing for possible alterations in amyloid plaque load
and markers of brain lipid peroxidation.

2. Materials and Methods

2.1. Materials

Methyl-tert-butyl ether (MTBE), chloroform and methanol were HPLC grade and purchased
from Thermo Scientific, Scoresby, VIC, Australia. Analytical grade ammonium acetate was
from Crown Scientific, Moorebank, NSW, Australia. Screw thread vials (4 mL) and wide
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mouth vials (1.8 mL) with PTFE/silicone septa caps were from Grace Davison, Rowville,
VIC, Australia. The internal lipid standard mixture contained AA (Avanti Polar Lipids
purchased

from

Auspep,

Tullamarine,

VIC,

Australia)

and

F2-isoprostanes

in

chloroform/methanol (2:1, vol:vol). F2-isoprostanes F2III-ISP (8-iso-prostaglandin F2) and
F2VI-ISP (5S,9,11,-trihydroxy-1,1,1-trihomo-18,19,20-trinor-8-prosta-2Z,6E-dien1-oic acid) were purchased from Cayman Chemicals (Ann Arbor, MI, USA). Other reagents
including analytical grade butylated hydroxytoluene (BHT) and sodium hydroxide (98%
minimum) were from Sigma Aldrich, Sydney, NSW, Australia.

2.2. Transgenic mice

Three strains of mice were used to generate amyloidogenic AD mice with either increased
neuronal expression of apoD or a complete lack of apoD. We used the APP-PS1 AD mouse
model expressing chimeric mouse/human APP695swe/Swedish mutations (K595N/M596L)
and mutant human PS1 (PS1/∆E9) obtained from the Jackson Laboratory (Bar Harbor, USA;
Strain name, B6.Cg-Tg AβPPswePSEN1dE9)85Dbo/J; Stock #005864) and maintained as
double hemizygotes on a C57BL/6J background as described previously (Cheng et al., 2013;
Jankowsky et al., 2004). This AD mouse model is on a pure (backcrossed > 10 generations)
C57BL6 background and has well characterised plaque pathology (Garcia-Alloza et al.,
2006). These mice have a pronounced AD phenotype with amyloid deposits by 6 months of
age which is accompanied by neuron loss and hippocampal atrophy by 12 months (GarciaAlloza et al., 2006). The generation and characterisation of the apoD gene knockout (DKO)
mice and the human apoD transgenic (DTG) mice (DTG mice selectively expresses human
apoD in neurons under the control of the Thy-1 promoter) was previously described
(Ganfornina et al., 2008). The neuron-specific expression of human apoD in the DTG mice
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has been established (Do Carmo et al., 2008; Ganfornina et al., 2008). Hemizygous APP-PS1
mice were crossed with either DKO or DTG mice to generate APP-PS1/DKO+/- and APPPS1/DTG+/- breeders. These mice were used to generate APP-PS1/DKO+/+ and APPPS1/DTG+/+ and littermate APP-PS1 control groups. As previously described (Jankowsky et
al., 2004), the expression of the human mutant AβPPswe and PSEN1dE9 segregate together.
All test animals were hemizygous with respect to the AβPPswe and PSEN1dE9 transgenes, in
line with standard protocols for amyloidogenic AD mouse models (Gotz and Ittner, 2008;
Higgins and Jacobsen, 2003). All mice were on a pure (backcrossed > 10 generations)
C57BL6 background. Genotyping of the APP-PS1, DKO and DTG mice has been described
previously (Ganfornina et al., 2008; Kim et al., 2010). Test animals were females at ~11
months of age (DKO Study: APP-PS1, n = 9, 49.7 ± 4.7 weeks old; APP-PS1/DKO n = 7,
50.7 ± 4.3 weeks old; DTG Study: APP-PS1, n = 8, 44.2 ± 1.6 weeks old; APP-PS1/DTG n =
7, 44.2 ± 2.1 days old). Female APP-PS1 mice were used as they accumulate a more sever
amyloid pathology at an early age compared to male APP-PS1 mice (Wang et al., 2003).
Ethics approval was from the University of Wollongong and the University of New South
Wales animal ethics committees.

2.3. Tissue preparation

Mice were euthanized by CO2 asphyxiation and transcardially perfused with ice-cold
phosphate buffered saline (PBS). The brains were removed and sagittally divided and the
hippocampus dissected from the right hemisphere before snap freezing and storage at -80˚C.
The left hemisphere was immersion fixed in 4% paraformaldehyde in 0.1 M phosphate buffer
(PB) at 4˚C for three days, then preserved in 30% (w/v) sucrose in 0.1M PB with 0.01%
sodium azide at 4˚C until sectioning. Six sets of 45 m sagittal cryo-sections were collected
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and stored at -20˚C in antifreeze solution for histological and immunohistochemiical analysis.
One part of pulverized hippocampus (~15mg) was homogenized in 10 volumes of 140 mM
NaCl, 3 mM KCl, 25 mM Tris (pH 7.4), containing 1% Nonidet P-40 and Roche complete
protease inhibitors (TBS/NP40 extraction buffer) using a Precellys 24 homogenizer (2 x 30s,
6000 g). Homogenates were centrifuged at 20,817 g for 15 min at 4˚C and the TBS/NP40soluble supernatant aliquoted into several tubes and stored at −80˚C until use in western
blotting and ELISA experiments. Protein concentration was measured using the bicinchoninic
acid (BCA) method.

2.4. PCR

Mouse genotyping was assessed on DNA extracted from tail tips using the ISOLATE
Genomic DNA mini kit (BIO-52032, Bioline Sydney, Australia) as described previously
(Borchelt et al., 1996; Do Carmo et al., 2009; Ganfornina et al., 2008). For brain mRNA
analysis, total RNA from the cortex was extracted using TriReagent and RNA concentrations
determined using a Nanodrop 1000 spectrophotometer (Thermo Fisher Scientific) and
260/230 nm and 260/280 nm absorbance ratios used to determine RNA purity. Two μg of
total RNA was used for reverse transcription with oligo dT(18) primers using the Tetro
cDNA Synthesis kit (Bioline, Sydney, Australia). For apoD mRNA validation, PCR was
conducted on an Eppendorf Master cycler or a Bio-Rad Thermalcycler using My Taq HS Mix
(Bioline, Sydney, Australia) with the following primer pairs: human apoD: forward, 5' - TGC
AGG AGA ATT TTG ACG TG - 3', reverse, 5' - AGG TTA ACT GGG GTG GCT TC - 3';
mouse apoD: forward, 5' - CCA CCG GCA CCC TAC TGG ATC - 3', reverse, 5' - CGG
GCA GTT CGC TTG ATC TGT - 3'. The PCR amplicons separated in 2% agarose gels were
visualized using by Gel Logic 212 Pro image system (Carestream Health, Inc. NY, USA).
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Mouse apoE mRNA analysis was carried out in a Roche Lightcycler 480 real-time PCR
system using SensiFAST SYBR No-ROX kit (Bioline, Sydney, Australia), following the
manufacturer's protocol with primer pairs: forward, 5'- AAC AGA CCC AGC AAA TAC
GCC - 3', reverse, 5' - CTC ATT GAT TCT CCT GGG CC - 3'. The level of apoE expression
was calculated using the comparative threshold cycle (Ct) value method using the formula
2−ΔΔCt.

2.5. A ELISA

A40 and A42 in TBS/NP40-soluble hippocampal homogenates were quantified using
ELISA kits (Cat #SIG-38954 and SIG-38956, Covance, North Ryde NSW, Australia or
EZBRAIN-SET, EMD Millipore Corporation, Billerica, MA, USA) following the
manufacturer's instructions as described (Kim et al., 2013). The insoluble hippocampal
homogenate fractions were prepared by centrifugation of TBS/NP40-soluble hippocampal
homogenates at 20,817 x g for 15 min at 4°C and the pellet was homogenized with 6 volumes
of 6.25 M guanidine HCl (gHCl) and assayed by ELISA, as previously described in detail
(Kim et al., 2013), to give an estimate of “insoluble” A40 and A42 levels in the
hippocampus. Samples were diluted 1:10 (Aβ40) or 1:50 (Aβ42) and assayed in duplicate.
Aβ40 and Aβ42 levels in extracts were calculated by comparing samples to the Aβ standard
curves.

2.6. Plaque histology

Staining of hippocampal tissues with thioflavine S (ThS) and anti-A monoclonal antibody
6E10 was performed as described previously (Kim et al., 2013). In brief, sagittal sections (45
8

m thick, free floating) were rinsed extensively with TBS to remove cryo-protectants and
immersed in distilled H2O (2 min), Harris hematoxylin (2 min), distilled H2O (3 min), 1%
(w/v) ThS (Sigma T1892, 3 min), distilled H2O (3 min), 1% (v/v) acetic acid (20 min),
distilled H2O (3 min), and mounted in buffered glycerol. Three sections per mouse were
analysed from the cortical and hippocampal regions between lateral 1 mm to lateral 2 mm
from the midline as defined using a mouse brain atlas (Franklin and Paxinos, 2007). Images
were captured using a Nikon TE2000 microscope equipped with a SPOT digital camera
(Diagnostic Instruments) and Image-Pro Plus 6.1 software (Media Cybernetics, Silver Spring
MD, USA). Hippocampal ThS-positive plaque load was quantified as percentage coverage of
the area of interest (measured as μm2) using ImageJ. Data are presented as relative values
compared to the relevant control group (which was arbitrarily assigned a value of 1.0).

For amyloid plaque immunohistochemistry, sections were pre-treated with 95% formic acid
for 5 minutes, rinsed with tap water, then quenched with 1% H2O2 for 30 min. After blocking,
sections were incubated with biotin-6E10 monoclonal antibody (1:5000, Cat# SIG-39340,
Covance,), for 16 h at 4˚C, followed by streptavidin-HRP (Sigma,S2438, 1:4000), 1 h at
22˚C. The sections were developed using DAB substrate (SK-4105, Vector Laboratories) and
scanned at 20X magnification (Aperio Digital Pathology System, Aperio Technologies). The
percentage of the area occupied by immunoreactive products above background staining was
measured in the hippocampal region (three sections per mouse, between lateral 1 mm to
lateral 2.5 mm from the midline) using ImageJ software. Data are presented as relative values
compared to the relevant control group (which was arbitrarily assigned a value of 1.0).

2.7. Immunohistochemistry methods for apoD, BACE1, GFAP and Iba1 staining
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After removal of cryo-protectants, consecutivesetsofsagittalsections(45μmthick)fromthe
different mouse groups were immunostained for BACE1, GFAP and Iba1 with the
peroxidase-3,3′-diaminobenzidine

(DAB)

method

as

previously

described

for

immunohistochemistry (Kim et al., 2013). Briefly, sections were treated with 1% H2O2 in
PBS for 30 minutes after antigen retrieval by boiling the sections in citrate buffer (0.01M, pH
6.0 for 5min). Sections were then pre-incubated in 5% horse serum in PBS with 0.5% Triton
X-100 for 1 h, and then incubated with the primary antibodies at 4˚C overnight (BACE1
1:400, rabbit monoclonal, Cat# 5606, Cell Signalling; GFAP, 1:2000, rabbit polyclonal Cat#
Z0334, DAKO; Iba1, 1:2000, rabbit polyclonal, Cat# 019-19741, Wako). Sections were
further reacted with a biotinylated pan-specific secondary antibody (goat anti-rabbit IgG,
Cat# B7398, Sigma) at 1:200 for 2 h, and subsequently with Streptavidin−Peroxidase
Polymer (1:5000, Sigma Cat# S2438) for 1 h. Immunoreaction product was visualized in
SIGMAFAST™DAB with Metal Enhancer (Cat# D0426). The mounted slides were scanned
at 20X magnification with Aperio Digital Pathology System (Aperio Technologies, USA).

The methods used for apoD immunofluorescence detection were as described previously
(Lagares et al., 2007; Li et al., 2007). In brief, free-floating sagittal brain sections from WT,
APP-PS1, APP-PS1/DTG mice were probed using an antibody raised against human apoD
(1:400, clone EPR2916, rabbit monoclonal Cat# Ab108191, Abcam) alone, or with antiNeuN (1:500, Clone A60, mouse monoclonal Cat# MAB377, EMD-Millipore) doublestaining to localize apoD in neurons. Another set of sections from APP-PS1/DKO mice were
used for double-labelling with an A antibody (WO2 hybridoma culture media, 1:50, gift or
Dr Qiao-Xin Li and Prof Colin Masters, University of Melbourne). Where indicated, the
additional antibodies (BACE1 1:500, GFAP 1:2000, Iba1 1:1000) were also included.
Donkey anti-rabbit Alexa flour 488 (1:250, Cat# A-21206, Life Technologies) and donkey
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anti-mouse IgG conjugated Alexa flour-594 (1:500, Cat# A-21203, Life Technologies) were
used as the secondary antibodies. After mounting with anti-fade media (Cat#10981, Sigma),
coverslips were sealed with nail polish, and the samples were stored at 4˚C. Images were
captured using 4X and 10X objective lens (with an ocular lens at 10X) in a Nikon TE2000
microscope equipped with a SPOT digital camera (Diagnostic Instruments) and Image-Pro
Plus 6.1 software (Media Cybernetics, Silver Sprin MD, USA). High-power images were
taken using a Leica TCS SP5 confocal laser-scanning microscope (Leica Microsystems,
Germany). Optical density in the area of interest was measured using ImageJ
(http://rsb.info.nih.gov/ij/) as described previously (Kim et al., 2013), using freehand
selection to outline hippocampal and cortical regions (sampling section immunolabelling
tools). Data were compared to appropriate control mouse groups for both the DKO and DTG
groups andstatisticaldifferenceswereassessedusingthestudent’st-test where P < 0.05 was
considered significant.

2.8. Western blotting

TBS/NP40-soluble homogenates were analysed by SDS-PAGE (~15 to 50 μg protein per
lane) and western blotting using antibodies to: apoD (sc-34760 or sc-166612, Santa Cruz,
1:5000), apoE (Cat# 178479, Merck Millipore, 1:5,000), APP (WO2 monoclonal provided by
Dr Qiao-Xin Li and Prof Colin Masters, University of Melbourne, 1:200), APP C-terminal
fragments (A8717, Sigma, 1:10,000), BACE1 (Ab108392, clone EPR3956, Abcam, 1:5,000)
NRG-1 C-terminal fragments (SC-348, Santa Cruz, 1:500), HNE (recognizes proteins
modified by the aldehydic lipid peroxidation end product, 4-hydroxynonenal) (MAB3248,
R&D Systems, 1:2,000) and β-actin (A5060, Sigma, 1:10,000). Signals were detected using
species-specific

HRP-conjugated

secondary
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antibodies

(Dako)

and

enhanced

chemiluminescence and quantified using ImageJ software. Integrated optical density data
were normalized to -actin levels and expressed as relative values.

2.9. Analysis of F2-isoprostanes by GC-MS

Lipid extracts (from ~5 mg tissue) were hydrolysed overnight for GC-MS analysis of F2isoprostanes as described previously (Abbott et al., 2013). Samples were loaded onto preconditioned solid phase extraction columns (UCT CUQAX223 3 ml; United Chemical
Technologies, Bristol, USA) and washed with 2ml of 40 mM formic acid (pH 4.5) containing
40% (v/v) methanol and 2ml hexane/MTBE (1:1). F2-isoprostanes and fatty acids were eluted
from the SPE columns with MTBE containing 20% methanol and 1% formic acid. The F2isoprostane and fatty acid fraction was dried down under nitrogen and derivatised with 30 µl
of pentafluorobenzylbromide (PFBBr) (10% in acetonitrile) and 15 µl of N,Ndiisopropylethylamine (DIPEA) (10% in acetonitrile) at 37°C for 30 min. Excess reagents
were evaporated under nitrogen. The F2-isoprostane PFBenzyl ester was derivatised with 20
µl acetonitrile plus 20 µl BSTFA+1% TMCS for 1 hour at 37°C. The derivatised samples
were dried under nitrogen, reconstituted in 40 µl toluene and analysed using an Agilent
7000B triple quadrupole mass selective detector interfaced with an Agilent 7890A GC system
gas chromatograph, equipped with an automatic sampler and a computer workstation.
Selected-reaction monitoring (SRM) was performed using the negative chemical ionisation
(NCI) mode (70eV) with argon as the reagent gas (1.25 ml/min) and the collision gas (0.6
ml/min). The ion source was maintained at 150°C and the quadrupoles at 150°C. For F2isoprostane analysis, derivatised samples (1 µl) were injected splitless into the GC injection
port. Column temperature was increased from 180°C to 280°C, at 40°C/min, then to 292°C,
at 2°C/min, and finally to 305°C, at 50°C/min, with a final hold of 4 min. Quantification of
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F2-isoprostanes (F2III-ISP + F2VI-ISP) was achieved by comparison of specific SRM
transitions with their corresponding heavy isotope internal standards. Relative molar response
factors for each analyte were calculated from calibration curves constructed from different
concentrations in triplicate, AA and DHA (1 to 25 g) and F2-isoprostanes (0.25 – 2.5 ng),
and showed good linearity (r2 > 0.98).

2.10. Data analysis

Quantitative data are presented as mean ± SE (represented by the error bars) from 7 to 9 mice
unless stated otherwise. Statistical differences were assessed using the student’s t-test where
P < 0.05 was considered significant.

3. Results

3.1. Generation of APP-PS1 mice that lack apoD or express human apoD in neurons

We crossed APP-PS1 mice with both apoD knockout (DKO) and human apoD
overexpressing transgenic (DTG) mice to assess the impact this may have on the amyloid
phenotype of this AD mouse model. Analysis of murine apoD using PCR methods confirmed
the absence of apoD mRNA in the brain of APP-PS1/DKO mice (Fig. 1A). The presence of
human apoD mRNA was similarly confirmed by PCR to be present only in the APPPS1/DTG line (Fig. 1B). The loss of apoD protein was confirmed the APP-PS1/DKO mice
(Fig. 1C). As previous studies have suggested there may be compensatory changes between
apoE and apoD in mice (Terrisse et al., 1999) and humans (Kim et al., 2009), possibly due to
a partial overlap in lipid-binding functions, we also assessed apoE protein levels. ApoD
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deletion did not significantly alter apoE protein levels, although we did observe a trend (p =
0.06) for 14% lower apoE in the APP-PS1/DKO mice (Fig. 1C and 1E). Further analysis of
apoE mRNA indicated there was no change associated with apoD loss (Fig. 1F).

Regarding the APP-PS1/DTG mice, previous studies have confirmed the neuron-specific
expression of human apoD (under the control of the Thy-1 promoter) in these mice (Do
Carmo et al., 2008; Ganfornina et al., 2008). This is a valid model for the study of
neurological disease as even though the vast majority of apoD in the brain is expressed by
glial cells, under pathological conditions apoD is also detected in neuronal populations (Desai
et al., 2005; Elliott et al., 2010; Kalman et al., 2000; Rassart et al., 2000). We used an
antibody that cross-reacts with both mouse and human apoD in order to assess any possible
change in global apoD levels in APP-PS1/DTG mice. The neuronal expression of human
apoD resulted in a modest but statistically significant increase (by 20%) in total apoD protein
levels (Fig. 1D and 1E). Although the presence of apoD in neurons from human apoD
transgenic DTG mice has been previously demonstrated (Do Carmo et al., 2008; Ganfornina
et al., 2008) (and O. Najyb and E. Rassart, unpublished data), we also confirmed this in the
present studies using immunohistochemical techniques. These experiments confirmed that
neuronal apoD was increased in the APP-PS1/DTG mice compared to the APP-PS1 control
mice (Fig. 2). Analysis of the apoD staining indicated the majority of the apoD was neuronal
(although non-neuronal staining was also detected, arrows Fig. 2G-I). Quantitative analysis of
apoD staining indicated a significant overall increase in apoD levels of 21% in the APPPS1/DTG mice compared to the APP-PS1 control mice (Fig. 2J). It is noteworthy that
endogenous mouse apoD levels were also higher in the APP-PS1 mice as compared to wild
type C57Bl6J mice (Fig. 2J). The total increase in apoD levels in the APP-PS1/DTG
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therefore reflects up-regulation of endogenous mouse apoD (in agreement with previous
studies, (Thomas et al., 2001)) and human apoD resulting from transgenic expression.

Neither apoE protein (Fig. 1D and 1E) nor apoE mRNA (Fig. 1F) was altered in the APPPS1/DTG mice compared to control APP-PS1 mice. The APP-PS1/DKO and APP-PS1/DTG
mice we generated therefore represented an appropriate model to probe for apoD-related
changes in amyloid pathology that are free of any confounding influences associated with
altered apoE levels.

3.2. Deletion of apoD significantly increases amyloid plaque pathology in APP-PS1 mice

The extent of cortical A deposition was assessed in sagittal sections from 11-month-old
APP-PS1 and APP-PS1/DKO mice using both 6E10 and ThS staining as quantitative markers
of plaque pathology. Immunohistochemical staining demonstrated numerous 6E10 positive
plaques in the hippocampus and cortex of APP-PS1 mice (Fig. 3A). Hippocampal 6E10
plaque pathology was approximately doubled in the APP-PS1/DKO mice compared to the
APP-PS1 mice (Fig. 3A and 3C). ThS staining was also used as an additional marker of
amyloid plaque load. ThS binds to -sheet rich structures including components of both
amyloid plaques and neurofibrillary tangles. ThS staining confirmed that hippocampal plaque
pathology was significantly increased in the APP-PS1/DKO mice compared to the APP-PS1
control mice (Fig. 3B and 3C). Very similar increases in amyloid plaque and ThS staining
were also detected in the cortex of APP-PS1/DKO as compared to the control APP-PS1 mice
(Fig. 3D).
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We also used an ELISA method to assess hippocampal levels of soluble Aβ40 and Aβ42 in
both APP-PS1 mice and APP-PS1/DKO mice. Despite the increase in plaque pathology noted
above, levels of soluble Aβ40 and Aβ42 were not significantly changed by the loss of apoD in
APP-PS1 mice (Fig. 4A). The pellets from the soluble homogenate fractions were also
dissolved in gHCl and assessed by ELISA to give an indicator of “insoluble”Aβ40 andAβ42
levels. Although a trend for increased levels of Aβ40 was noted (Fig. 4C), this was not
statistically significant. Overall, these data indicate that the deletion of apoD in APP-PS1
mice results in a significant increase in hippocampal amyloid plaque pathology.

3.3. Neuronal expression of human apoD significantly decreases amyloid plaque pathology
in APP-PS1 mice

Using the same suite of techniques utilised in the analysis of plaque pathology in APPPS1/DKO mice, a parallel study focusing on neuronal expression of human apoD in the APPPS1/DTG mice was conducted. In contrast to results arising from apoD deletion, neuronal
expression of human apoD led to a significant reduction in hippocampal and cortical amyloid
plaque pathology as assessed by both 6E10 and ThS staining of the APP-PS1/DTG brain
sagittal sections compared to control APP-PS1 tissues (Fig. 5A-D). Furthermore, levels of
soluble Aβ40 in the APP-PS1/DTG hippocampus were reduced to less than half the level
detected in control APP-PS1 mice (Fig. 4B) and there was a trend (p = 0.077) for a similar
reduction in the insolubleAβ40 in the same group comparison (Fig 4D). Interestingly, levels
of insoluble (but not soluble) Aβ42 were significantly reduced (by 34%) in the APP-PS1/DTG
mice compared to control APP-PS1 mice (Fig. 4D). The reasons for the selective effect of
apoD overexpression on different A species is not entirely clear. Of potential relevance, it is
known hat the ratio of A42:A40 changes dramatically depending on the stage of amyloid
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pathology in APP-PS1 mice (Wang et al., 2003). Overall, these data indicate that neuronal
expression of human apoD significantly decreases hippocampal amyloid plaque pathology in
APP-PS1 mice.

3.4. Impact of apoD modulation on APP processing

Based on the significant changes in amyloid plaque load detected in association with
modulation of apoD levels in the APP-PS1 mouse brain, we went on to assess potential
alterations in the APP processing pathway that could contribute to these changes. APP is
sequentially cleaved by - and -secretases to generate A peptides of 39 to 42 amino acids,
or it may undergo processing via the -secretase pathway which is non-amyloidogenic as the
-cleavage occurs in the middle of the A sequence and thereby precludes A generation (De
Strooper et al., 2010; Kang et al., 1987). During these proteolytic steps, membrane associated
APP C-terminal fragments (CTFs) are generated that, along with an analysis of full length
APP, can be used as a de facto measure of changes in the rate of APP proteolytic processing
in the brain. The major APP CTFs formed result from: the -cleavage, referred to as the
“C83” CTF; the -(BACE1)-cleavage, referred to as the “C99” CTF; and, at lower levels, the
-secretase products of both C83 and C99 cleavage, referred to as the APP intracellular
domain (AICD) fragment. The major APP CTF fragments used for quantification in the
present study have an apparent MW of 9 kDa and 12 kDa, consistent with C83 and C99,
respectively. The western blot bands we used for quantification are thus outlined on the fulllength western blots included as supplementary data (Suppl. Fig. 1). Comparing the APP-PS1
and APP-PS1/DKO mice (Fig. 6A and 6C), the levels APP CTFs were found to be
significantly increased (by 44%). This was associated with significantly increased (by ~2fold) levels of BACE1 in the APP-PS1/DKO mice (Fig. 6B and 6C). Note that the increased
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BACE1 in the APP-PS1/DKO mice was not likely to be due to the deletion of apoD per se, as
BACE1 levels were essentially identical when WT and apoD null mice were compared
(Suppl. Fig 2). Based on these results, we also assessed the same tissues for CTFs derived
from BACE1-mediated cleavage of neuregulin-1 (NRG1), another well characterized BACE1
substrate (Fleck et al., 2012; Fleck et al., 2013; Hu et al., 2006). In this case, we detected a
significant 27% increase in NRG1 CTFs in the APP-PS1/DKO mice (Fig. 6B and 6C).

Expression levels of these same proteins were also investigated in the brain homogenates
derived from the APP-PS1/DTG mice. Intriguingly, and in contrast to the data derived from
the APP-PS1/DKO mouse study, we found that the levels of APP CTFs were significantly
reduced (by 40%) in the APP-PS1/DTG mice (Fig. 6D and 6F). Non-significant trends for
decreased levels of BACE1 and NRG1 CTFs were also apparent (Fig. 6E and 6F). Although
not statistically significant across all parameters, these data point towards an inverse
association between apoD levels and BACE1 levels / activity in the brain.

To gain additional information regarding the potential modulation of BACE1 expression in
the hippocampus, tissue sections were immunostained and the intensity of staining quantified.
BACE1 appeared to be strongly expressed in the CA3 region of the hippocampus in all mice
studied (Fig. 7). We also detected increased BACE1 staining in the vicinity of amyloid
plaques as a general phenomenon across all mouse groups (typical examples are provided in
Supplemental Figure 3). The quantitative analysis indicated hippocampal BACE1 levels were
significantly increased by 25% in the APP-PS1/DKO mice compared to the APP-PS1
controls, whereas no change in BACE1 staining level was detected in the APP-PS1/DTG
mice compared to the APP-PS1 controls (Fig. 7B). These data are in agreement with the
western blot analysis of BACE1 (Fig. 6). As alterations in amyloid plaque pathology may be
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associated with gliosis (Yan et al., 2009), we also assessed potential changes in glial markers
GFAP (astrocytes) and Iba1 (microglia). An increase in hippocampal Iba1 (but not GFAP)
staining was detected in APP-PS1/DKO mice compared to the APP-PS1 controls (Fig. 7),
whereas no changes in either Iba1 or GFAP were detected in the APP-PS1/DTG mice
compared to the APP-PS1 controls (Fig. 7). Colocalization immunohistochemical studies
indicated that BACE1, GFAP and Iba1 staining were all clearly detected in the vicinity of
amyloid plaques (Suppl. Fig. 3). It is therefore possible that at least part of the modulation of
BACE1 levels is a response to the development of amyloid pathology. Consistent with this
notion, there is evidence to suggest that a vicious cycle exists whereby A and BACE1 both
reciprocally up-regulate each others expression levels (Chami and Checler, 2012).

3.5. Impact of apoD modulation on markers of lipid peroxidation

Increased brain lipid peroxidation is associated with AD and is also a feature of AD mouse
models, including the APP-PS1 line (Abdul et al., 2008; Markesbery and Carney, 1999).
Based on the knowledge that apoD plays a significant role in protecting against lipid
peroxidation in the brain (Ganfornina et al., 2008), we also assessed the mouse brain tissues
for two markers of lipid peroxidation, HNE-modified proteins and F2-isoprostanes. We
previously reported that HNE-modified proteins in the range of ~56 kDa were positively
associated with age in the human brain and inversely correlated with apoD expression (Kim
et al., 2009), therefore similar protein markers were the focus in the present study. Although
trends consistent with a lipid antioxidant function of apoD were noted (Fig. 8), no statistically
significant changes in the abovementioned lipid peroxidation markers were detected. Altered
lipid oxidation status therefore does not appear to be a major contributing factor in the altered
AD pathology we have described in association with brain apoD levels in the APP-PS1
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mouse model herein. Furthermore, the significant changes in plaque pathology associated
with altered apoD expression we report do not appear to significantly modify brain lipid
oxidation status.

4. Discussion

ApoD is a 29 kDa glycoprotein member of the lipocalin family (Rassart et al., 2000). The
apoD crystal structure reveals an eight-stranded antiparallel -barrel flanked by an -helix
(Eichinger et al., 2007). The -barrel encloses a conically shaped hydrophobic cavity referred
to as the apoD ligand binding pocket. Early studies suggested that apoD binds a range of
lipids including arachidonic acid (AA), cholesterol and several steroids (Dilley et al., 1990;
Lea, 1988; Morais Cabral et al., 1995; Pearlman et al., 1973). More recent studies indicate
that binding of lipids in the apoD binding pocket is in fact quite specific (Eichinger et al.,
2007; Oakley et al., 2012; Vogt and Skerra, 2001). Progesterone, AA and retinoic acid bind
to the apoD binding pocket with high affinity whereas pregnenolone and specific eicosanoids
(e.g. 12-HETE and 5,15-diHETE) also bind but with reduced affinity (Dilley et al., 1990;
Lea, 1988; Morais Cabral et al., 1995; Ruiz et al., 2013). In addition to the binding pocket,
apoD may also interact with lipids via a cluster of “exposed” hydrophobic residues residing
in 3 of its extended loops (Eichinger et al., 2007; Oakley et al., 2012). These exposed
residues generate a region of surface hydrophobicity close to the open end of the binding
pocket that facilitates apoD association with high-density lipoprotein (HDL) particles and is
also thought to permit insertion of apoD into cellular lipid membranes (Eichinger et al.,
2007).
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Several previous studies have shown that apoD levels are up-regulated in the AD brain
(Bhatia et al., 2013; Terrisse et al., 1998; Thomas et al., 2003; Thomas et al., 2001), that there
is a marked increase of neuronal apoD expression in AD (Desai et al., 2005; Kalman et al.,
2000), and that apoD is found in amyloid plaques (Desai et al., 2005). Three studies have also
reported associations between variations in the APOD gene and AD risk (Chen et al., 2008;
Desai et al., 2003; Helisalmi et al., 2004). However, the direct role that apoD may play in
modulating the course of AD has not been previously addressed. Our findings provide the
first evidence that apoD expression levels do influence amyloid plaque pathology. It is
intriguing that neuronal apoD expression is induced in human AD and in AD mouse models,
yet a further increase, as achieved by transgenic neuronal expression in our current studies, is
still able to significantly reduce amyloid plaque pathology. A similar outcome has also been
reported in other studies using the same experimental approach to understand the function of
proteins that may be involved in the regulation of AD pathology. For example, expression of
the lipid transport protein ATP-binding cassette transporter A1 (ABCA1) is increased in the
brain in human AD and AD mouse models (Kim et al., 2010), yet transgenic expression of
ABCA1 in AD mice significantly reduces plaque pathology (Wahrle et al., 2008). It may be
that for apoD, and other “protective” proteins like ABCA1, the homeostatic increase in
protein expression is only partially protective, or is protective only later in the disease process
when the up-regulation is stimulated in response to pathogenic stimuli. In contrast, transgenic
expression of the protective protein could provide optimal protection through all stages of life
and AD development, thus resulting in greater therapeutic efficacy.

Loss-of-function Drosophila mutants for the apoD homolog glial lazarillo (GLaz) were more
sensitive to oxidative stress and contained higher concentrations of lipid peroxidation
products; suggesting a function for apoD/GLaz in lipid peroxide (L-OOH) scavenging
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(Sanchez et al., 2006). In agreement with this, over-expression of GLaz in transgenic
Drosophila lines resulted in an increased resistance to oxidative stress, a 29% extension in
lifespan and protection against hyperoxia-induced behavioural decline (Walker et al., 2006).
In addition, expression of human apoD reduced the accumulation of aldehydic end-products
of lipid peroxidation in old flies (Muffat et al., 2008). Similarly, the expression of human
apoD in mouse neurons provided protection against paraquat-induced brain lipid peroxidation
(Ganfornina et al., 2008). Since apoD provides lipid antioxidant protection in the brain
(Ganfornina et al., 2008), one plausible mechanistic explanation could be due to the
secondary regulation of A production by brain lipid oxidation products. Previous studies
have shown that oxidative stress and the products of lipid peroxidation, HNE in particular,
up-regulate the expression of BACE1 leading to increased neuronal A production (Paola et
al., 2000; Tamagno et al., 2005). This would be consistent with the increase in BACE1
protein levels we observed in the APP-PS1/DKO mice as compared to their APP-PS1
littermates (Fig. 6). Although the converse (i.e. reduced BACE1) was not observed in the
APP-PS1/DTG experiment, a decrease in APP CTFs including the BACE1 product (C99)
was detected (Fig. 6). This provides initial evidence that the modulation of A pathology by
apoD may be mediated by BACE1. The precise mechanisms by which apoD modulates AD
pathology remain to be resolved and, based on our current findings, this is an area that
appears to warrant further investigation.

One limitation in our study is that we have not assessed additional groups of animals at
earlier times points. Such future studies might reveal if BACE1 modulation plays a role in the
earlier stage during development of AD pathology. Also related to this, at the time of animal
cull at 11 months (a time chosen to ensure reasonable plaque load was present in all APP-PS1
mice), we detected only non-significant trends in HNE and F2-isoprostane markers of lipid
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peroxidation (Fig. 8). It is possible that with advancing stages of plaque pathology, a
response to the predicted oxidativestresscanbemountedthatissufficientto“normalise”the
lipid oxidative damage. We have shown previously in studies of post-mortem human brain
that there is a coordinated up-regulation of apoD and additional antioxidant enzymes
(superoxide dismutase 1 and glutathione peroxidase 3) associated with aging and increased
levels of HNE-modified proteins (Kim et al., 2009). Follow up studies that focus on early
time points of amyloid pathology development in these mice may add additional mechanistic
insights.

ApoD may also regulate AD pathology via modulation of eicosanoids such as 5s-, 12s- and
15s-hydroperoxyeicosatetraenoic acids (HpETEs) that play a key role in brain inflammatory
pathways (Phillis et al., 2006), and have been shown to be regulated by apoD in vitro (Bhatia
et al., 2012; Oakley et al., 2012). Altered eicosanoid metabolism would be predicted to have
significant impact on neuronal signalling and neuroinflammation in the AD context
(Sanchez-Mejia and Mucke, 2010). Furthermore, pro-inflammatory conditions induced by
lipopolysaccharide (LPS) have been shown to increase apoD expression in a time- and dosedependent manner and the elements in the apoD promoter responsible (NF-B, AP-1 and
APRE-3) were confirmed to all be involved in the inflammatory response (Do Carmo et al.,
2007). ApoD may also have an impact on the inflammatory pathways associated with AD
pathology via regulation of specific cytokines. Previous studies in the Thy-1/ApoD (DTG)
mice indicate that apoD protects against viral encephalitis by reducing both TNF and IL1
expression and increasing IL6 expression (Do Carmo et al., 2008). This could potentially tie
in with the concept regarding modulation of eicosanoid metabolism by apoD, as DTG mice
have reduced phospholipase-A2 (PLA2) activity in the brain (Do Carmo et al., 2008). Based
on the facts that: (i), PLA2 is required to release arachidonic acid form phospholipids to
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provide substrates for bioactive eicosanoids (Sanchez-Mejia and Mucke, 2010); (ii), PLA2 is
up-regulated by TNF and IL1 (Adibhatla and Hatcher, 2007); (iii), that inflammation
promotes A production and exacerbates amyloid plaque pathology (Sastre et al., 2003;
Sastre et al., 2008; Yamamoto et al., 2007), it is reasonable to expect that apoD may regulate
AD progression via such anti-inflammatory processes. In a preliminary screen, however, we
did not detect changes in cortical levels of TNF or IL in either the APP-PS1/DKO or APPPS1/DTG mice compared to their APP-PS1 littermates (H. Li, S. Sanz Muñoz and B. Garner,
unpublished data). Interestingly, both of the proposed mechanisms by which apoD may
regulate amyloid plaque pathology (i.e. oxidative stress and inflammation) intersect at the
BACE1 nexus (Chami and Checler, 2012).

In summary, the current studies using both gene knockout and neuronal overexpression
approaches provide clear evidence that apoD regulates amyloid plaque pathology in a mouse
model of AD. The role that apoD plays in the regulation of lipid oxidative stress, and
neuroinflammation and the impact this has on BACE1-dependent and -independent pathways
contributing to AD pathology is an area that appears to warrant further study.
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FIGURE LEGENDS

Fig. 1. Generation of APP-PS1/DKO and APP-PS1/DTG mice. APP-PS1/DKO mice and
APP-PS1/DTG mice that either lack apoD or express human apoD in neurons, respectively,
were generated as described in the “Materials and Methods” section. Cortical samples were
assessed for mouse apoD mRNA (A) and human apoD mRNA (B) with each compared to the
appropriate APP-PS1 littermate control mice (A, B). ApoD and apoE protein levels were
assessed by western blotting and -actin was used as a loading control (C, D). Relative
protein and mRNA levels (where appropriate) were quantified using optical density of the
scanned gels/blots (E, F). Representative samples are shown in the gels/blots. Quantitative
data are means of 7 to 9 samples with the SE shown by the error bars. * P < 0.05; *** P <
0.0001; # trend, P = 0.05 to 0.06.

Fig. 2. ApoD immunohistochemical analysis in APP-PS1 and APP-PS1/DTG mice.
Sagittal sections from wild type (WT), APP-PS1 and APP-PS1/DTG cortex were stained for
apoD and NeuN to assess the extent of neuronal apoD localization. ApoD staining intensity
was assessed using Image J software and the data expressed relative to the WT mice that
were assigned an arbitrary relative plaque value of 1.0 (C). The white arrows indicate nonneuronal staining. Quantitative data are means of 3 to 4 samples with the SE shown by the
error bars. ** P < 0.05 (for comparison of APP-PS1 and APP-PS1/DTG apoD staining).
Scalebarin“F”=200m.Scalebarin“I”=20m.

Fig. 3. Impact of apoD loss on amyloid plaque pathology in APP-PS1 mice. Sagittal
sections from APP-PS1 and APP-PS1/DKO mice were stained with 6E10 (A) or ThS (B) to
assess amyloid plaque load. The area fraction of the hippocampal and cortical regions
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occupied by plaques was calculated using Image J software and the data expressed as plaque
levels relative to the APP/PS1 mice that were assigned an arbitrary relative plaque value of
1.0 (C-D). Grey bars, APP-PS1 group; black bars, APP-PS1/DKO group. Scale bars = 500
m. All quantitative data are expressed as mean ± SE (represented by the error bars). * P <
0.05, ** P < 0.01.

Fig. 4. Impact of apoD modulation on soluble and insoluble A species. Quantification of
Aβ40 and Aβ42 levels in APP-PS1/DKO and APP-PS1/DTG hippocampal homogenates,
relative to their appropriate APP-PS1 control mouse groups, was assessed by ELISA. For all
samples, the “soluble” (A-B) and “insoluble” (guanidine HCl solubilised) A species were
quantified. Grey bars, APP-PS1 group; black bars, APP-PS1/DKO (DKO) or APP-PS1/DTG
(DTG) group, as indicated. Scale bars = 500 m. All quantitative data are expressed as mean
± SE (represented by the error bars). * P < 0.05, ** P < 0.01,

#

P = 0.08 (non-significant

trend).

Fig. 5. Impact of transgenic neuronal expression of human apoD on amyloid plaque
pathology in APP-PS1 mice. Sagittal sections from APP-PS1 and APP-PS1/DTG mice were
stained with 6E10 (A) or ThS (B) to assess amyloid plaque load. The area fraction of the
hippocampal region occupied by plaques was calculated using Image J software and the data
expressed as plaque levels relative to the APP/PS1 mice that were assigned an arbitrary
relative plaque value of 1.0 (C). Grey bars, APP-PS1 group; black bars, APP-PS1/DTG
group. Scale bars = 500 m. All quantitative data are expressed as mean ± SE (represented by
the error bars). * P < 0.05, ** P < 0.01.
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Fig. 6. Impact of apoD modulation on APP processing. Hippocampal homogenates derived
from APP-PS1/DKO, APP-PS1/DTG and their appropriate control APP-PS1 groups were
probed for the proteins listed by western blotting (A, B, D, E). Representative blots (n = 4 to
5 samples for each group) are shown. -Actin is used as a loading control. Integrated optical
density for blots of all samples is shown (C, F). Grey bars, APP-PS1 group; black bars, APPPS1/DKO or APP-PS1/DTG group. Levels are expressed relative to APP-PS1 mice and
presented as mean + SE. * P < 0.05, *** P < 0.0001. APP, amyloid precursor protein; CTFs,
APP C-terminal fragments; BACE1, beta-site APP cleaving enzyme-1; NRG1 CTFs,
neuregulin-1 C-terminal fragments. Note that consistent with previous data (Ghosal et al.,
2009), the major APP CTFs are tentatively assigned as C99 (CTF, 12 kDa) and C83 (CTF,
9.2 kDa). The identity of a third apparent APP CTF band at ~15 kDa is unknown and its
levels were not used in the data presented (although inclusion of this band in the analysis did
not alter the data). For quantification, the optical density of the two major APP CTF bands
were measured together. Full-length western blots related to APP CTF proteolytic products
are provided in Supplementary materials (Suppl. Fig. 1).

Fig. 7. Impact of apoD modulation on hippocampal BACE1, GFAP, and Iba1 levels
assessed by immunohistochemistry. Sagittal sections from APP-PS1/DKO and APPPS1/DTG mice and their appropriate control APP-PS1 groups were immunostained for
BACE1, GFAP and Iba1 (A), and the staining intensity quantified using ImageJ software.
The data are presented as protein levels relative to the APP/PS1 mice that were assigned an
arbitrary relative value of 1.0 (B). Grey bars, APP-PS1 group; black bars, APP-PS1/DKO
(DKO) or APP-PS1/DTG (DTG) group. Statistical differences are expressed relative to APPPS1 control mice and data presented as mean + SE, n = 4 to 5 sections per group. * P < 0.05.
Scale bar = 500 m.
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Fig. 8. Impact of apoD modulation on markers of lipid oxidative stress. Brain
homogenates derived from APP-PS1/DKO, APP-PS1/DTG and their appropriate control
APP-PS1 groups were probed for the proteins modified by the lipid peroxidation aldehydic
product 4-hydroxynonenal (HNE) by western blotting (A, B). Representative blots (n = 4 to 7
samples for each group) are shown. -Actin is used as a loading control. Integrated optical
density for blots of all samples is shown (C). Grey bars, APP-PS1 group; black bars, APPPS1/DKO or APP-PS1/DTG group. Comparison of F2-isoprostane levels in APP-PS1/DKO
or APP-PS1/DTG groups and their appropriate control APP-PS1 groups. Lipids were
extracted, the F2-isoprostane fraction was purified by solid phase extraction and F2isoprostane PFBenzyl esters were prepared and derivatised with BSTFA and TMCS for
analysis using GC-MS. The F2-isoprostanes were quantified by comparison to internal
standards. Data are expressed as pg F2-isoprostane per g of arachidonic acid (AA). Levels
are expressed relative to APP-PS1 mice and presented as mean + SE.
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SUPPLEMENTARY FIGURE LEGENDS

Suppl. Fig. 1. Impact of apoD modulation on APP processing – full length western blots
demonstrating position of APP CTFs. Hippocampal homogenates derived from APPPS1/DKO, APP-PS1/DTG and their appropriate control APP-PS1 groups were probed for the
APPandAPPproteolyticproducts.Theregionmarkedas“CTFs”representthepanelsthat
are shown for APP CTFs in Fig. 6. Note that consistent with previous data (Ghosal et al.,
2009), the major APP CTFs are tentatively assigned as C99 (CTF, 12 kDa) and C83 (CTF,
9.2 kDa). The identity of a third apparent APP CTF band at ~15 kDa is unknown and its
levels were not used in the data presented (although inclusion of this band in the analysis did
not alter the data). For quantification, the optical density of the two major APP CTF bands
were measured together (shown by the dashed red line boxes in the blots on the right hand
side). APP, amyloid precursor protein; CTFs, APP C-terminal fragments.

Suppl. Fig. 2. Hippocampal BACE1 expression is not altered in apoD null mice.
Hippocampal homogenates derived from wild type (WT) and apoD null (apoD-/-) mice (in the
absence of the APP-PS1 background) were probed for apoD, BACE1, and -actin by western
blotting. The representative blots indicate no change in BACE1 levels in either male of
female apoD-/-mice as compared to WT control mice.

Suppl. Fig. 3. Distribution pattern of hippocampal BACE1, GFAP and IBa1 with
amyloid plaques by double-staining immunofluorescence. Sagittal sections from brains of
APP-PS1/DKO mice were used for double-labelling with an A antibody and a BACE1
antibody to demonstrate the distribution of BACE1 and its relationships with amyloid plaque
(A). The confocal images demonstrate that BACE1 is localize around WO2-positive plaques
39

and in the CA3 region where the highest BACE1 level is detected. Staining for glial markers
GFAP (astrocytes) and Iba1 (microglia) close to the hippocampal CA3 region also
demonstrated a close association of these glial markers around WO2-positive plaques (B).
Scale bar in“A”= 500 m,scalebarsin“B”= 100 m.
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*Highlights (for review)

Research highlights
- Brain apoD levels are increased with aging and Alzheimer’s disease
- It was unclear if apoD modulates amyloid pathology in vivo
- ApoD deletion exacerbated amyloid pathology in the APP/PS1 mice
- Transgenic neuronal apoD expression reduced amyloid pathology in the
APP/PS1 mice

